Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery
Journal of Pediatric Endocrinology and Metabolism · 2023
DOI: 10.1515/jpem-2022-0605 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2023. Verfasst von Li-Li Pei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China. Hauptthemen laut MEDLINE: Craniopharyngioma, Human Growth Hormone, Dwarfism, Pituitary, Hypopituitarism. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Childhood-onset craniopharyngiomas (CPs) have a high incidence of growth hormone deficiency (GHD) leading to growth failure and metabolic disorders. We aim to evaluate the benefits and risks of recombinant human growth hormone replacement therapy (GHRT) in postoperative children.
Methods
We retrospectively analyzed auxological and metabolic parameters and adverse events before and after GHRT of 44 children after CP surgery.
Results
The median duration of GHRT was 24 months (IQR, 12.5–36). Growth velocity (GV) increased significantly after different treatment duration (TD) compared with baseline (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Beijing Tiantan Hospital, Capital Medical University, Beijing, P.R. China.
Zitieren
APA
Pei, L. L., Guo, Y., Chen, H., & Zhong, L. Y. (2023). Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2022-0605
Vancouver
Pei LL, Guo Y, Chen H, Zhong LY. Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery. Journal of Pediatric Endocrinology and Metabolism. 2023. doi:10.1515/jpem-2022-0605
BibTeX
@article{Pei2023,
author = {Pei, Li-Li and Guo, Ying and Chen, Han and Zhong, Li-Yong},
title = {Benefits and risks evaluation of recombinant human growth hormone replacement therapy in children with GHD after craniopharyngioma surgery},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2023},
doi = {10.1515/jpem-2022-0605}
}
EUVIMED